News
Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...
Shares in Novo Nordisk have risen sharply on new weight-loss data with an injectable formulation of new obesity candidate amycretin.
Researchers conducted the REDEFINE 1 and REDEFINE 2 clinical trials to assess the effect of CagriSema on weight loss in obesity with or without type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback